Message Font: Serif | Sans-Serif
No. of Recommendations: 2
yeah no kidding... a 50% move just on an analyst call? about what will happen in a year? I mean, it's an aggressive call, but still.

and whoooosh. Down 33% today on actual news.
GTx Inc. (GTXI) said the U.S. Food and Drug Administration has halted its clinical trials for Capesaris, a potential advanced prostate cancer and hormonal treatment, due to an increased risk of blood clots.

The biopharmaceutical company said the FDA's clinical hold notification affects its Phase II loading-dose finding clinical trial, Phase IIb maintenance-dose finding clinical trial, and its Phase II clinical trial in men with castration-resistant prostate cancer.

GTx said it found an increased risk of venous thromboembolic events, or blood clots, in subjects treated with 1000 milligrams or more of Capesaris, and it asked the FDA to discuss changes in its clinical development program.

Print the post  


When Life Gives You Lemons
We all have had hardships and made poor decisions. The important thing is how we respond and grow. Read the story of a Fool who started from nothing, and looks to gain everything.
Contact Us
Contact Customer Service and other Fool departments here.
Work for Fools?
Winner of the Washingtonian great places to work, and Glassdoor #1 Company to Work For 2015! Have access to all of TMF's online and email products for FREE, and be paid for your contributions to TMF! Click the link and start your Fool career.